Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771453 | 0.92 | SCN2A (0.37) | KEAP1NFE2L2SCN2ALMNAMAPT | |
| SCHEMBL6775462 | 0.89 | KIF11 (0.39) | RXFP1KIF11 | |
| SCHEMBL6775914 | 0.88 | KIF11 (0.37) | KIF11 | |
| SCHEMBL6781865 | 0.85 | MAP2K4 (0.39) | KIF11 | |
| SCHEMBL6782059 | 0.85 | SCN9A (0.39) | MEN1KMT2AKIF11 | |
| SCHEMBL6770619 | 0.84 | PARP1 (0.35) | RXFP1KIF11 | |
| SCHEMBL6776008 | 0.84 | MAP4K4 (0.38) | MEN1KMT2AKIF11 | |
| SCHEMBL6771095 | 0.84 | NPBWR1 (0.34) | MEN1KMT2AKIF11 | |
| SCHEMBL6775671 | 0.83 | IDH2 (0.36) | L3MBTL1KIF11 | |
| SCHEMBL3580321 | 0.83 | KIF11 (0.38) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977741-B1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | EP | claimed |
| US-6297261-B1 | POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE | NEUROSEARCH A/S (DK) | 2001-10-02 | — | — | US | claimed |
| EP-3622953-A1 | COMBINATION TREATMENT OF CANCER | Scandion Oncology A/S (DK) | 2020-03-18 | — | — | EP | disclosed |
| US-6696475-B2 | N-PHENYL-N'-(2-CARBOXYPHENYL) UREA, FOR EXAMPLE; CHLORIDE CHANNEL BLOCKERS; SUCH AS FOR TREATING BONE METABOLIC DISORDERS | NEUROSEARCH A/S (DK) | 2004-02-24 | — | — | US | disclosed |
| EP-0977741-B1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| US-6297261-B1 | POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE | NEUROSEARCH A/S (DK) | 2001-10-02 | — | — | US | disclosed |
| EP-0977741-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047879-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | KCNB1, KCNH2, KCNJ2 | KEAP1 609/4885NFE2L2 1024/4885SCN2A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.